Cross Country Healthcare Reports Second Quarter 2012 Results
For the six months ended
"Second quarter revenue was below expectations due in large part to the
delay of a scheduled, large electronic medical record (EMR)
implementation project, which had been fully staffed by us. In addition,
our earnings performance was below expectations because our cost
structure was too high relative to our revenue and we experienced a
larger than anticipated increase in direct costs in our nurse and allied
staffing business," said
"While we have seen a very significant increase in demand since February
lows, our nurse and allied contract booking activity in the second
quarter did not immediately mirror this sharp upturn and we have only
just begun to generate meaningful sequential booking momentum in the
past two months. Furthermore, while our second quarter results in this
segment were disappointing, since the end of the first quarter we have
signed up managed service provider (MSP) accounts that we believe
utilize more than
"Looking at our other staffing businesses, both the physician staffing
and clinical trial services businesses — which combined accounted for
38% of total revenue — achieved year-over-year and sequential growth in
the second quarter. Meanwhile, both businesses in our other human
capital management services segment — which accounted for 8% of total
revenue — were weaker than anticipated," said
Nurse and
For the second quarter of 2012, the nurse and allied staffing business
segment (travel and per diem nurse and allied health staffing) generated
revenue of
Segment staffing volume decreased 1% from both the prior year quarter
and sequentially. Travel staffing volume increased slightly
year-over-year, but decreased 1% sequentially while per diem staffing
volume decreased 10% year-over-year and 2% sequentially. The average
revenue per FTE per day for the second quarter of 2012 was
For the first six months of 2012, segment revenue increased 1% to
For the second quarter of 2012, the physician staffing business segment
generated revenue of
For the first six months of 2012, segment revenue increased slightly to
Clinical Trial Services
For the second quarter of 2012, the clinical trial services segment
generated revenue of
For the first six months of 2012, segment revenue increased 7% to
Other Human Capital Management Services
For the second quarter of 2012, the other human capital management
services business segment (education and training and retained search)
generated revenue of
For the first six months of 2012, segment revenue increased 2% to
Debt Outstanding and Credit Facility
During the second quarter of 2012, the Company reduced its debt by
On
Additional information regarding this new credit agreement can be
obtained from the Company's Report on Form 8-K filed with the
Stock Repurchase Program Update
During the second quarter of 2012, the Company did not repurchase any
shares of its common stock. As of
Guidance for Third Quarter 2012
The following statements are based on current management expectations. Such statements are forward-looking and actual results may differ materially. These statements do not include the potential impact of any future mergers, acquisitions or other business combinations, any impairment charges or valuation allowances, write-off of debt issuance costs or significant legal proceedings. For the third quarter of 2012, the Company expects:
-
Revenue to be in the
$126.0 million to $129.0 million range. - Gross profit margin to be approximately 26.0%.
- Adjusted EBITDA margin to be in the 2.5% to 3.0% range. Adjusted EBITDA, a non-GAAP financial measure, is defined in the accompanying financial statement tables.
-
Earnings per diluted share to be in the range of
$0.01 to $0.03 .
Quarterly Conference Call
The Company will hold its quarterly conference call on
Non-GAAP (Generally Accepted Accounting Principles) Financial Measures
This press release and accompanying financial statement tables reference non-GAAP financial measures. Such non-GAAP financial measures are provided as additional information and should not be considered substitutes for, or superior to, financial measures calculated in accordance with U.S. GAAP. Such non-GAAP financial measures are provided for consistency and comparability to prior year results; furthermore, management believes they are useful to investors when evaluating the Company's performance as it excludes certain items that management believes are not indicative of the Company's operating performance. Such non-GAAP financial measures may differ materially from the non-GAAP financial measures used by other companies. The financial statement tables that accompany this press release include a reconciliation of each non-GAAP financial measure to the most directly comparable U.S. GAAP financial measure and a more detailed discussion of each financial measure; as such, the financial statement tables should be read in conjunction with the presentation of these non-GAAP financial measures.
About
In addition to historical information, this press release contains
statements relating to our future results (including certain projections
and business trends) that are "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and are subject to the "safe harbor" created by those
sections. Forward-looking statements consist of statements that are
predictive in nature, depend upon or refer to future events. Words such
as "expects", "anticipates", "intends", "plans", "believes",
"estimates", "suggests", "appears", "seeks", "will" and variations of
such words and similar expressions intended to identify forward-looking
statements. Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results and
performance to be materially different from any future results or
performance expressed or implied by these forward-looking statements.
These factors include, without limitation, the following: our ability to
attract and retain qualified nurses, physicians and other healthcare
personnel, costs and availability of short-term housing for our travel
nurses and physicians, demand for the healthcare services we provide,
both nationally and in the regions in which we operate, the functioning
of our information systems, the effect of existing or future government
regulation and federal and state legislative and enforcement initiatives
on our business, our clients' ability to pay us for our services, our
ability to successfully implement our acquisition and development
strategies, the effect of liabilities and other claims asserted against
us, the effect of competition in the markets we serve, our ability to
successfully defend the Company, its subsidiaries, and its officers and
directors on the merits of any lawsuit or determine its potential
liability, if any, and other factors set forth in Item 1A. "Risk
Factors" in the Company's Annual Report on Form 10-K for the year ended
December 31, 2011, and our other
Although we believe that these statements are based upon reasonable
assumptions, we cannot guarantee future results and readers are
cautioned not to place undue reliance on these forward-looking
statements, which reflect management's opinions only as of the date of
this press release. There can be no assurance that (i) we have correctly
measured or identified all of the factors affecting our business or the
extent of these factors' likely impact, (ii) the available information
with respect to these factors on which such analysis is based is
complete or accurate, (iii) such analysis is correct or (iv) our
strategy, which is based in part on this analysis, will be successful.
The Company undertakes no obligation to update or revise forward-looking
statements. All references to "we," "us," "our," or "Cross Country" in
this press release mean
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Consolidated Statements of Operations | ||||||||||||||||||||||||||||||||||||||
(Unaudited, amounts in thousands, except per share data) | ||||||||||||||||||||||||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||
|
|
|
|
June 30, | ||||||||||||||||||||||||||||||||||
2012 | 2011 | 2012 | 2012 | 2011 | ||||||||||||||||||||||||||||||||||
Revenue from services | $ | 126,272 | $ | 126,042 | $ | 126,672 | $ | 252,944 | $ | 248,088 | ||||||||||||||||||||||||||||
Operating expenses: | ||||||||||||||||||||||||||||||||||||||
Direct operating expenses | 94,405 | 91,433 | 93,068 | 187,473 | 180,503 | |||||||||||||||||||||||||||||||||
Selling, general and administrative expenses (a) | 30,742 | 29,475 | 31,120 | 61,862 | 58,346 | |||||||||||||||||||||||||||||||||
Bad debt expense | 281 | (149 | ) | 111 | 392 | 89 | ||||||||||||||||||||||||||||||||
Depreciation | 1,559 | 1,804 | 1,593 | 3,152 | 3,645 | |||||||||||||||||||||||||||||||||
Amortization | 819 | 877 | 818 | 1,637 | 1,842 | |||||||||||||||||||||||||||||||||
Impairment charge (b) | 18,732 | - | - | 18,732 | - | |||||||||||||||||||||||||||||||||
Total operating expenses | 146,538 | 123,440 | 126,710 | 273,248 | 244,425 | |||||||||||||||||||||||||||||||||
(Loss) income from operations | (20,266 | ) | 2,602 | (38 | ) | (20,304 | ) | 3,663 | ||||||||||||||||||||||||||||||
Other (income) expenses: | ||||||||||||||||||||||||||||||||||||||
Foreign exchange (gain) loss | (153 | ) | 6 | 71 | (82 | ) | 23 | |||||||||||||||||||||||||||||||
Interest expense | 581 | 722 | 629 | 1,210 | 1,450 | |||||||||||||||||||||||||||||||||
Other expense (income), net | 133 |
|
(78 | ) | 36 | 169 | (161 | ) | ||||||||||||||||||||||||||||||
(Loss) income before income taxes | (20,827 | ) | 1,952 | (774 | ) | (21,601 | ) | 2,351 | ||||||||||||||||||||||||||||||
Income tax (benefit) expense | (6,323 | ) | 379 | (190 | ) | (6,513 | ) | 571 | ||||||||||||||||||||||||||||||
Net (loss) income | $ | (14,504 | ) | $ | 1,573 | $ | (584 | ) | $ | (15,088 | ) | $ | 1,780 | |||||||||||||||||||||||||
Net (loss) income per common share: | ||||||||||||||||||||||||||||||||||||||
Basic | $ | (0.47 | ) | $ | 0.05 | $ | (0.02 | ) | $ | (0.49 | ) | $ | 0.06 | |||||||||||||||||||||||||
Diluted | $ | (0.47 | ) | $ | 0.05 | $ | (0.02 | ) | $ | (0.49 | ) | $ | 0.06 | |||||||||||||||||||||||||
Weighted average common shares outstanding: | ||||||||||||||||||||||||||||||||||||||
Basic | 30,799 | 31,148 | 30,766 | 30,783 | 31,126 | |||||||||||||||||||||||||||||||||
Diluted | 30,799 | 31,218 | 30,766 | 30,783 | 31,204 | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Reconciliation of Non-GAAP Financial Measures | ||||||||||||||||||||||||||||||||||||||
Adjusted EBITDA, Adjusted pretax (loss) income, Adjusted net (loss) income and Adjusted net (loss) income per diluted share (c) (d) |
||||||||||||||||||||||||||||||||||||||
(Unaudited, amounts in thousands) | ||||||||||||||||||||||||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||
|
|
|
|
June 30, | ||||||||||||||||||||||||||||||||||
2012 | 2011 | 2012 | 2012 | 2011 | ||||||||||||||||||||||||||||||||||
(Loss) income from operations | $ | (20,266 | ) | $ | 2,602 | $ | (38 | ) | $ | (20,304 | ) | $ | 3,663 | |||||||||||||||||||||||||
Depreciation | 1,559 | 1,804 | 1,593 | 3,152 | 3,645 | |||||||||||||||||||||||||||||||||
Amortization | 819 | 877 | 818 | 1,637 | 1,842 | |||||||||||||||||||||||||||||||||
Impairment charge (b) | 18,732 | - | - | 18,732 | - | |||||||||||||||||||||||||||||||||
Equity compensation | 731 | 832 | 638 | 1,369 | 1,476 | |||||||||||||||||||||||||||||||||
Adjusted EBITDA (c) | $ | 1,575 | $ | 6,115 | $ | 3,011 | $ | 4,586 | $ | 10,626 | ||||||||||||||||||||||||||||
Adjusted EBITDA Margin (c) | 1.2 | % | 4.9 | % | 2.4 | % | 1.8 | % | 4.3 | % | ||||||||||||||||||||||||||||
(Loss) income before income taxes | $ | (20,827 | ) | $ | 1,952 | $ | (774 | ) | $ | (21,601 | ) | $ | 2,351 | |||||||||||||||||||||||||
Impairment charge (b) | 18,732 | - | - | 18,732 | - | |||||||||||||||||||||||||||||||||
Adjusted pretax (loss) income (d) | (2,095 | ) | 1,952 | (774 | ) | (2,869 | ) | 2,351 | ||||||||||||||||||||||||||||||
Income tax (benefit) expense | (6,323 | ) | 379 | (190 | ) | (6,513 | ) | 571 | ||||||||||||||||||||||||||||||
Tax effect of impairment charge (b) | 6,710 | - | - | 6,710 | - | |||||||||||||||||||||||||||||||||
Adjusted net (loss) income (d) | $ | (2,482 | ) | $ | 1,573 | $ | (584 | ) | $ | (3,066 | ) | $ | 1,780 | |||||||||||||||||||||||||
Net (loss) income per common share - diluted | $ | (0.47 | ) | $ | 0.05 | $ | (0.02 | ) | $ | (0.49 | ) | $ | 0.06 | |||||||||||||||||||||||||
Less: Impairment charge, net of taxes, per diluted share | (0.39 | ) | - | - | (0.39 | ) | - | |||||||||||||||||||||||||||||||
Adjusted net (loss) income per diluted share (d) | $ | (0.08 | ) | $ | 0.05 | $ | (0.02 | ) | $ | (0.10 | ) | $ | 0.06 | |||||||||||||||||||||||||
Weighted average common shares outstanding used in the calculation of non-GAAP adjusted net (loss) income per diluted share | 30,799 | 31,218 | 30,766 | 30,783 | 31,204 | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Condensed Consolidated Balance Sheets * |
||||||||||||||||||||||||||||||||||||||
(Unaudited, amounts in thousands) | ||||||||||||||||||||||||||||||||||||||
|
December 31, | |||||||||||||||||||||||||||||||||||||
2012 | 2011 | |||||||||||||||||||||||||||||||||||||
Assets | ||||||||||||||||||||||||||||||||||||||
Current assets: | ||||||||||||||||||||||||||||||||||||||
Cash and cash equivalents | $ | 6,207 | $ | 10,648 | ||||||||||||||||||||||||||||||||||
Short-term cash investments | 1,661 | 1,691 | ||||||||||||||||||||||||||||||||||||
Accounts receivable, net | 73,672 | 71,802 | ||||||||||||||||||||||||||||||||||||
Deferred tax assets | 11,264 | 10,401 | ||||||||||||||||||||||||||||||||||||
Income taxes receivable | 3,431 | 2,123 | ||||||||||||||||||||||||||||||||||||
Prepaid expenses | 6,992 | 7,441 | ||||||||||||||||||||||||||||||||||||
Other current assets | 637 | 701 | ||||||||||||||||||||||||||||||||||||
Total current assets | 103,864 | 104,807 | ||||||||||||||||||||||||||||||||||||
Property and equipment, net | 10,180 | 12,018 | ||||||||||||||||||||||||||||||||||||
Trademarks, net | 52,067 | 52,053 | ||||||||||||||||||||||||||||||||||||
Goodwill, net | 124,674 | 143,344 | ||||||||||||||||||||||||||||||||||||
Other identifiable intangible assets, net | 19,569 | 21,195 | ||||||||||||||||||||||||||||||||||||
Debt issuance costs, net | 832 | 1,199 | ||||||||||||||||||||||||||||||||||||
Non-current deferred tax assets | 4,807 | - | ||||||||||||||||||||||||||||||||||||
Other long-term assets | 1,257 | 1,294 | ||||||||||||||||||||||||||||||||||||
Total assets | $ | 317,250 | $ | 335,910 | ||||||||||||||||||||||||||||||||||
Liabilities and Stockholders' Equity | ||||||||||||||||||||||||||||||||||||||
Current liabilities: | ||||||||||||||||||||||||||||||||||||||
Accounts payable and accrued expenses | $ | 9,064 | $ | 9,018 | ||||||||||||||||||||||||||||||||||
Accrued employee compensation and benefits | 17,570 | 16,332 | ||||||||||||||||||||||||||||||||||||
Current portion of long-term debt | 3,959 | 16,998 | ||||||||||||||||||||||||||||||||||||
Other current liabilities | 5,565 | 4,002 | ||||||||||||||||||||||||||||||||||||
Total current liabilities | 36,158 | 46,350 | ||||||||||||||||||||||||||||||||||||
Long-term debt | 32,269 | 25,048 | ||||||||||||||||||||||||||||||||||||
Non-current deferred tax liabilities | - | 58 | ||||||||||||||||||||||||||||||||||||
Other long-term liabilities | 14,345 | 15,154 | ||||||||||||||||||||||||||||||||||||
Total liabilities | 82,772 | 86,610 | ||||||||||||||||||||||||||||||||||||
Commitments and contingencies | ||||||||||||||||||||||||||||||||||||||
Stockholders' equity: | ||||||||||||||||||||||||||||||||||||||
Common stock | 3 | 3 | ||||||||||||||||||||||||||||||||||||
Additional paid-in capital | 243,666 | 243,170 | ||||||||||||||||||||||||||||||||||||
Accumulated other comprehensive loss | (3,603 | ) | (3,373 | ) | ||||||||||||||||||||||||||||||||||
(Accumulated deficit) retained earnings | (5,588 | ) | 9,500 | |||||||||||||||||||||||||||||||||||
Total stockholders' equity | 234,478 | 249,300 | ||||||||||||||||||||||||||||||||||||
Total liabilities and stockholders' equity | $ | 317,250 | $ | 335,910 | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Segment Data (e) | ||||||||||||||||||||||||||||||||||||||
(Unaudited, amounts in thousands) | ||||||||||||||||||||||||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||
|
% of Total |
|
% of Total |
|
% of Total |
|
% of Total |
|
% of Total |
|||||||||||||||||||||||||||||
2012 | 2011 | 2012 | 2012 | 2011 | ||||||||||||||||||||||||||||||||||
Revenue from services: | ||||||||||||||||||||||||||||||||||||||
Nurse and allied staffing | $ | 67,617 | 54 | % | $ | 68,271 | 54 | % | $ | 69,537 | 55 | % | $ | 137,154 | 54 | % | $ | 135,128 | 54 | % | ||||||||||||||||||
Physician staffing | 30,939 | 24 | % | 30,603 | 24 | % | 29,259 | 23 | % | 60,198 | 24 | % | 60,039 | 24 | % | |||||||||||||||||||||||
Clinical trial services | 17,425 | 14 | % | 16,485 | 13 | % | 16,872 | 13 | % | 34,297 | 14 | % | 32,117 | 13 | % | |||||||||||||||||||||||
Other human capital management services | 10,291 | 8 | % | 10,683 | 9 | % | 11,004 | 9 | % | 21,295 | 8 | % | 20,804 | 9 | % | |||||||||||||||||||||||
$ | 126,272 | 100 | % | $ | 126,042 | 100 | % | $ | 126,672 | 100 | % | $ | 252,944 | 100 | % | $ | 248,088 | 100 | % | |||||||||||||||||||
Contribution income (f) | ||||||||||||||||||||||||||||||||||||||
Nurse and allied staffing | $ | 2,242 | $ | 5,633 | $ | 3,999 | $ | 6,241 | $ | 10,644 | ||||||||||||||||||||||||||||
Physician staffing | 2,677 | 2,903 | 2,407 | 5,084 | 5,665 | |||||||||||||||||||||||||||||||||
Clinical trial services | 1,560 | 1,552 | 1,323 | 2,883 | 2,844 | |||||||||||||||||||||||||||||||||
Other human capital management services | 275 | 946 | 1,110 | 1,385 | 1,336 | |||||||||||||||||||||||||||||||||
6,754 | 11,034 | 8,839 | 15,593 | 20,489 | ||||||||||||||||||||||||||||||||||
Unallocated corporate overhead | 5,910 | 5,751 | 6,466 | 12,376 | 11,339 | |||||||||||||||||||||||||||||||||
Depreciation | 1,559 | 1,804 | 1,593 | 3,152 | 3,645 | |||||||||||||||||||||||||||||||||
Amortization | 819 | 877 | 818 | 1,637 | 1,842 | |||||||||||||||||||||||||||||||||
Impairment charge (b) | 18,732 | - | - | 18,732 | - | |||||||||||||||||||||||||||||||||
(Loss) income from operations | $ | (20,266 | ) | $ | 2,602 | $ | (38 | ) | $ | (20,304 | ) | $ | 3,663 | |||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Other Financial Data | ||||||||||||||||||||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||||||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||
|
|
|
|
June 30, | ||||||||||||||||||||||||||||||||||
2012 |
2011 | 2012 | 2012 | 2011 | ||||||||||||||||||||||||||||||||||
Net cash provided by operating activities (in thousands) | $ | 2,402 | $ | 10,003 | $ | 1,401 | $ | 3,803 | $ | 11,376 | ||||||||||||||||||||||||||||
Nurse and allied staffing statistical data: |
||||||||||||||||||||||||||||||||||||||
FTEs (g) | 2,427 | 2,461 | 2,453 | 2,440 | 2,433 | |||||||||||||||||||||||||||||||||
Days worked (h) | 220,857 | 223,951 | 223,223 | 444,080 |
440,373 |
|||||||||||||||||||||||||||||||||
Average nurse and allied staffing revenue per FTE per day (i) | $ | 306 | $ | 305 | $ | 312 | $ | 309 | $ | 307 | ||||||||||||||||||||||||||||
Physician staffing statistical data: |
||||||||||||||||||||||||||||||||||||||
Days filled (j) | 21,447 | 21,737 | 20,617 | 42,064 | 42,405 | |||||||||||||||||||||||||||||||||
Revenue per day filled (k) | $ | 1,443 | $ | 1,408 | $ | 1,419 | $ | 1,431 | $ | 1,416 | ||||||||||||||||||||||||||||
*Certain prior year amounts have been reclassified to conform to the current period's presentation. |
||||||||||||||||||||||||||||||||||||||
(a) During the three and six months ended |
||||||||||||||||||||||||||||||||||||||
(b) Impairment charge in the three and six months ended |
||||||||||||||||||||||||||||||||||||||
(c) Adjusted EBITDA, a non-GAAP (Generally Accepted Accounting Principles) financial measure, is defined as (loss) income from operations before depreciation, amortization, impairment charge and non-cash equity compensation. Adjusted EBITDA should not be considered a measure of financial performance under GAAP. Management presents Adjusted EBITDA because it believes that Adjusted EBITDA is a useful supplement to (loss) income from operations as an indicator of operating performance. Management uses Adjusted EBITDA as one performance measure in its annual cash incentive program for certain members of its management team. In addition, management monitors Adjusted EBITDA for planning purposes, including compliance with its debt covenants. Adjusted EBITDA, as defined, closely matches the operating measure used in the Company's Debt Leverage Ratio and Minimum Fixed Charge Coverage Ratio as defined by its Credit Agreement. Management believes Adjusted EBITDA, as defined, is useful to investors when evaluating the Company's performance as it excludes certain items that management believes are not indicative of the Company's operating performance. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by the Company's consolidated revenue. | ||||||||||||||||||||||||||||||||||||||
(d) Adjusted pretax (loss) income, adjusted net (loss) income and adjusted net (loss) income per diluted share, non-GAAP financial measures, are defined as pretax (loss) income, net (loss) income, and net (loss) income per diluted shared before the non-cash impairment charge related to goodwill. Adjusted pretax (loss) income, adjusted net (loss) income and adjusted net (loss) income per diluted share should not be considered a measure of financial performance under GAAP and has been provided for consistency and comparability of the 2012 results with pretax (loss) income, net (loss) income and net (loss) income per diluted share in the prior periods. | ||||||||||||||||||||||||||||||||||||||
(e) Segment data provided is in accordance with the Segment Reporting Topic of the FASB ASC. | ||||||||||||||||||||||||||||||||||||||
(f) Defined as (loss) income from operations before depreciation, amortization, impairment charge and corporate expenses not specifically identified to a reporting segment. Contribution income is a financial measure used by management when assessing segment performance. | ||||||||||||||||||||||||||||||||||||||
(g) FTEs represent the average number of nurse and allied contract staffing personnel on a full-time equivalent basis. | ||||||||||||||||||||||||||||||||||||||
(h) Days worked is calculated by multiplying the FTEs by the number of days during the respective period. | ||||||||||||||||||||||||||||||||||||||
(i) Average revenue per FTE per day is calculated by dividing the nurse and allied staffing revenue by the number of days worked in the respective periods. Nurse and allied staffing revenue also includes revenue from permanent placement of nurses. | ||||||||||||||||||||||||||||||||||||||
(j) Days filled is calculated by dividing the total hours filled during the period by 8 hours. | ||||||||||||||||||||||||||||||||||||||
(k) Revenue per day filled is calculated by dividing the applicable revenue generated by the Company's physician staffing segment by days filled for the period presented. |
Director/Investor & Corporate Relations
hgoldman@crosscountry.com
Source:
News Provided by Acquire Media